These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 35773273)

  • 1. Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing.
    Jo S; Das S; Williams A; Chretien AS; Pagliardini T; Le Roy A; Fernandez JP; Le Clerre D; Jahangiri B; Chion-Sotinel I; Rozlan S; Dessez E; Gouble A; Dusséaux M; Galetto R; Duclert A; Marcenaro E; Devillier R; Olive D; Duchateau P; Poirot L; Valton J
    Nat Commun; 2022 Jun; 13(1):3453. PubMed ID: 35773273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stromal depletion by TALEN-edited universal hypoimmunogenic FAP-CAR T cells enables infiltration and anti-tumor cytotoxicity of tumor antigen-targeted CAR-T immunotherapy.
    Das S; Valton J; Duchateau P; Poirot L
    Front Immunol; 2023; 14():1172681. PubMed ID: 37251405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition.
    Ren J; Liu X; Fang C; Jiang S; June CH; Zhao Y
    Clin Cancer Res; 2017 May; 23(9):2255-2266. PubMed ID: 27815355
    [No Abstract]   [Full Text] [Related]  

  • 4. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
    Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
    Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
    Morgan MA; Büning H; Sauer M; Schambach A
    Front Immunol; 2020; 11():1965. PubMed ID: 32903482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paving the way towards universal treatment with allogenic T cells.
    Townsend MH; Bennion K; Robison RA; O'Neill KL
    Immunol Res; 2020 Feb; 68(1):63-70. PubMed ID: 32096010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiplex Genome-Edited T-cell Manufacturing Platform for "Off-the-Shelf" Adoptive T-cell Immunotherapies.
    Poirot L; Philip B; Schiffer-Mannioui C; Le Clerre D; Chion-Sotinel I; Derniame S; Potrel P; Bas C; Lemaire L; Galetto R; Lebuhotel C; Eyquem J; Cheung GW; Duclert A; Gouble A; Arnould S; Peggs K; Pule M; Scharenberg AM; Smith J
    Cancer Res; 2015 Sep; 75(18):3853-64. PubMed ID: 26183927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of chromosomal alteration after infusion of gene-edited allogeneic CAR T cells.
    Sasu BJ; Opiteck GJ; Gopalakrishnan S; Kaimal V; Furmanak T; Huang D; Goswami A; He Y; Chen J; Nguyen A; Balakumaran A; Shah NN; Hamadani M; Bone KM; Prashad S; Bowen MA; Pertel T; Embree HD; Gidwani SG; Chang D; Moore A; Leonard M; Amado RG
    Mol Ther; 2023 Mar; 31(3):676-685. PubMed ID: 36518079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Multidrug-resistant Engineered CAR T Cell for Allogeneic Combination Immunotherapy.
    Valton J; Guyot V; Marechal A; Filhol JM; Juillerat A; Duclert A; Duchateau P; Poirot L
    Mol Ther; 2015 Sep; 23(9):1507-18. PubMed ID: 26061646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutant B2M-HLA-E and B2M-HLA-G fusion proteins protects universal chimeric antigen receptor-modified T cells from allogeneic NK cell-mediated lysis.
    Guo Y; Xu B; Wu Z; Bo J; Tong C; Chen D; Wang J; Wang H; Wang Y; Han W
    Eur J Immunol; 2021 Oct; 51(10):2513-2521. PubMed ID: 34323289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genome-edited allogeneic donor "universal" chimeric antigen receptor T cells.
    Qasim W
    Blood; 2023 Feb; 141(8):835-845. PubMed ID: 36223560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protocol for Efficient Generation of Chimeric Antigen Receptor T Cells with Multiplexed Gene Silencing by Epigenome Editing.
    Azcona MSR; Mussolino C
    Methods Mol Biol; 2024; 2842():209-223. PubMed ID: 39012598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A versatile system for rapid multiplex genome-edited CAR T cell generation.
    Ren J; Zhang X; Liu X; Fang C; Jiang S; June CH; Zhao Y
    Oncotarget; 2017 Mar; 8(10):17002-17011. PubMed ID: 28199983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells.
    Qasim W; Zhan H; Samarasinghe S; Adams S; Amrolia P; Stafford S; Butler K; Rivat C; Wright G; Somana K; Ghorashian S; Pinner D; Ahsan G; Gilmour K; Lucchini G; Inglott S; Mifsud W; Chiesa R; Peggs KS; Chan L; Farzeneh F; Thrasher AJ; Vora A; Pule M; Veys P
    Sci Transl Med; 2017 Jan; 9(374):. PubMed ID: 28123068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CAR NK-92 cell-mediated depletion of residual TCR+ cells for ultrapure allogeneic TCR-deleted CAR T-cell products.
    Kath J; Du W; Martini S; Elsallab M; Franke C; Hartmann L; Drosdek V; Glaser V; Stein M; Schmueck-Henneresse M; Reinke P; Volk HD; Abou-El-Enein M; Wagner DL
    Blood Adv; 2023 Aug; 7(15):4124-4134. PubMed ID: 37196643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integration of a CD19 CAR into the TCR Alpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CAR T Cells.
    MacLeod DT; Antony J; Martin AJ; Moser RJ; Hekele A; Wetzel KJ; Brown AE; Triggiano MA; Hux JA; Pham CD; Bartsevich VV; Turner CA; Lape J; Kirkland S; Beard CW; Smith J; Hirsch ML; Nicholson MG; Jantz D; McCreedy B
    Mol Ther; 2017 Apr; 25(4):949-961. PubMed ID: 28237835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia.
    Hu Y; Zhou Y; Zhang M; Ge W; Li Y; Yang L; Wei G; Han L; Wang H; Yu S; Chen Y; Wang Y; He X; Zhang X; Gao M; Yang J; Li X; Ren J; Huang H
    Clin Cancer Res; 2021 May; 27(10):2764-2772. PubMed ID: 33627493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elucidation of CRISPR-Cas9 application in novel cellular immunotherapy.
    Quazi S
    Mol Biol Rep; 2022 Jul; 49(7):7069-7077. PubMed ID: 35122203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Universal CARs, universal T cells, and universal CAR T cells.
    Zhao J; Lin Q; Song Y; Liu D
    J Hematol Oncol; 2018 Nov; 11(1):132. PubMed ID: 30482221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing.
    Dimitri A; Herbst F; Fraietta JA
    Mol Cancer; 2022 Mar; 21(1):78. PubMed ID: 35303871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.